Table 2.
Multivariable prognostic model for overall and relative survival in THRLBCL.
| Variable | Overall survival | Relative survival a | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age: 18–50 years | Ref. | <0.001 | Ref. | <0.001 | |||
| 51–60 years | 1.39 | (0.77–2.48) | 1.26 | (0.66–2.42) | |||
| 61–70 years | 2.27 | (1.35–3.83) | 2.11 | (1.18–3.79) | |||
| 71–80 years | 2.74 | (1.57–4.79) | 2.48 | (1.32–4.65) | |||
| >80 years | 7.46 | (4.27–13.04) | 6.28 | (3.30–11.95) | |||
| Sex: male | Ref. | 0.41 | Ref. | 0.35 | |||
| Female | 1.16 | (0.82–1.64) | 1.21 | (0.81–1.79) | |||
| Race/ethnicity: white | Ref. | 0.52 | Ref. | 0.53 | |||
| Black | 1.24 | (0.79–1.95) | 1.27 | (0.77–2.08) | |||
| Asian / other | 0.65 | (0.16–2.67) | 0.65 | (0.14–2.95) | |||
| Comorbidity index: 0 | Ref. | 0.024 | Ref. | 0.018 | |||
| 1 | 0.78 | (0.47–1.30) | 0.82 | (0.46–1.45) | |||
| 2 | 1.20 | (0.55–2.64) | 1.29 | (0.54–3.07) | |||
| ≥3 | 3.17 | (1.39–7.20) | 3.62 | (1.53–8.52) | |||
| Stage: I/II | Ref. | 0.18 | Ref. | 0.23 | |||
| III/IV | 1.38 | (0.86–2.23) | 1.42 | (0.80–2.51) | |||
| B symptoms: present | Ref. | 0.06 | Ref. | 0.044 | |||
| Absent | 1.45 | (0.99–2.14) | 1.58 | (1.01–2.46) | |||
| Primary site: nodal | Ref. | 0.043 | Ref. | 0.024 | |||
| Extranodal | 2.00 | (1.02–3.90) | 2.31 | (1.12–4.79) | |||
| Reporting hospital: other | Ref. | 0.91 | Ref. | 0.99 | |||
| Academic/research | 1.02 | (0.72–1.44) | 1.00 | (0.67–1.49) | |||
CI: confidence interval; HR: hazard ratio; Ref.: reference level.
a
Relative survival adjusts for baseline mortality rate according to age, sex, race, and calendar year based on US national statistics, thus measuring lymphoma-related excess mortality.